⌕
Arrowhead Pharmaceuticals · ARWR · Nasdaq
Tenet 33 · Weak
Compare
$42.99−2.76%At closeTenet 33 · Weak
$42.99−1.22 (−2.76%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Arrowhead Pharmaceuticals (ARWR) Institutional Ownership

13F filers reported holding 9.1% of Arrowhead Pharmaceuticals (ARWR) shares as of Sep 30, 2026, across 200 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
9.1%
Sep 30, 2026
13F filers
200
quarter ended Sep 30, 2026
13F value
$852.8M
12.9M shares
Quarter's fund flow
Mild distribution
24 new · 26 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds trimmed or exited than added or entered, mild distribution (24 new · 69 increased · 70 reduced · 26 closed · 11 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 200 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Aug 18, 2026PERRY MICHAEL SdirectorDisposed · Open-market sale11,600$87.30↗
Aug 18, 2026OLUKOTUN ADEOYE YdirectorDisposed · Open-market sale2,000$86.96↗
Jun 15, 2026Cohen Matthew GregorydirectorAcquired · Grant / award11,882—↗
May 12, 2026Lu HongbodirectorDisposed · Open-market sale2,970$76.88↗
Apr 23, 2026Hamilton James CChief Medical OfficerDisposed · Open-market sale10,000$75.00↗
Apr 22, 2026Apel Daniel JosephChief Financial OfficerDisposed · Open-market sale3,208$70.11↗
Apr 22, 2026Apel Daniel JosephChief Financial OfficerDisposed · Open-market sale1,157$70.45↗
Apr 22, 2026Apel Daniel JosephChief Financial OfficerDisposed · Open-market sale8,730$71.92↗
Mar 5, 2026Hamilton James CChief Medical OfficerDisposed · Open-market sale10,000$64.19↗
Jan 6, 2026Apel Daniel JosephChief Financial OfficerAcquired · Grant / award75,000—↗
Jan 6, 2026Hamilton James CChief Medical OfficerAcquired · Grant / award75,000—↗
Jan 6, 2026O'Brien PatrickCOODisposed · Gift540—↗
Jan 6, 2026O'Brien PatrickCOODisposed · Gift540—↗
Jan 6, 2026O'Brien PatrickCOODisposed · Gift540—↗
Jan 6, 2026O'Brien PatrickCOODisposed · Gift440—↗
Jan 6, 2026O'Brien PatrickCOODisposed · Gift440—↗
Jan 6, 2026O'Brien PatrickCOOAcquired · Grant / award75,000—↗
Jan 5, 2026Hamilton James CChief Medical OfficerDisposed · Open-market sale4,625$61.24↗
Jan 5, 2026Hamilton James CChief Medical OfficerDisposed · Open-market sale6,090$62.28↗
Jan 5, 2026Hamilton James CChief Medical OfficerDisposed · Open-market sale14,792$63.01↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Arrowhead Pharmaceuticals do institutions hold?

13F filers reported holding 9.1% of Arrowhead Pharmaceuticals' shares as of Sep 30, 2026, across 200 filers.

How many 13F filers hold Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals was held by 200 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.